{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 17 of 128', '13.5.1 Pregnancy', '90', '13.6 Reporting of other events', '90', '13.6.1 Adverse events of special interest', '90', '13.6.2 Overdose', '91', '13.6.3', 'Medication error', '91', '13.6.4', 'Misuse', '91', '13.6.5', 'Abuse', '91', '13.6.6 Aggravation of condition', '92', '13.7 Follow-up for final outcome of adverse events', '92', '13.8 Handling of an urgent safety measure', '92', '14 Statistical methods', '93', '14.1 Sample size', '93', '14.2 Trial analysis sets', '93', '14.3 Statistical analysis', '94', '14.3.1 Disposition of subjects', '94', '14.3.2 Demographics and other baseline characteristics', '94', '14.3.3 Exposure and treatment compliance', '94', '14.3.4', 'Testing strategy', '95', '14.3.5 Analysis of primary efficacy endpoint', '95', '14.3.6 Analysis of secondary efficacy endpoints', '96', '14.3.7 Analysis of other endpoints', '97', '14.3.7.1 Analysis of patient-reported outcomes', '97', '14.3.7.2 Efficacy over time', '99', '14.3.7.3', 'Exploratory analyses', '99', '14.3.8', 'Analysis of pharmacodynamics and pharmacogenomics', '99', '14.3.9 Analysis of safety', '100', '14.3.9.1', 'Adverse events', '100', '14.3.9.2', 'Vital signs', '101', '14.3.9.3', 'Clinical laboratory evaluation', '101', '14.3.9.4 Subject assessment of local tolerability', '101', '14.3.10 Pharmacokinetics', '101', '14.3.11 Interim analysis', '101', '14.3.12 General principles', '102', '14.3.13 Handling of missing values', '102', '15 References', '103', 'Appendix 1: Definitions of adverse events and serious adverse events', '106']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 18 of 128', 'Appendix 2: Classification of adverse events', '108', 'Appendix 3: Trial governance considerations', '111', 'Appendix 3A: Regulatory and ethical considerations', '111', 'Appendix 3B: Informed consent process', '112', 'Appendix 3C: Subject and data confidentiality', '112', 'Appendix 3D: Record keeping, quality control, and data handling', '113', 'Appendix 3E: Registration, reporting and publication policy', '118', 'Appendix 3F: Insurance', '119', 'Appendix 3G: Financial disclosure', '119', 'Appendix 3H: Trial and site closure', '120', 'Appendix 3I: Responsibilities', '121', 'Appendix 4: Short version of eligibility criteria', '122', 'Appendix 5: Contact list', '124', 'Appendix 6: Protocol amendment history', '125', 'List of panels', 'Panel 1: Trial design', '27', 'Panel 2: Schedule of trial procedures', '28', 'Panel 3: Objectives and endpoints', '39', 'Panel 4: Identification of IMPs', '50', 'Panel 5: Prohibited medication', '55', 'Panel 6: Sequence of assessments', '62', 'Panel 7: Fitzpatrick skin classification', '64', 'Panel 8: Definition of subtypes of hand eczema', '67', \"Panel 9: Investigator's Global Assessment (IGA)\", '68', 'Panel 10: Description of the severity of each IGA sign or symptom', '69', 'Panel 11: HECSI severity score scale and area score scale', '70', 'Panel 12: Calculation of the total HECSI score', '70']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 19 of 128', 'Panel 13: Clinical laboratory tests', '74', 'Panel 14: Subject assessment of local tolerability after IMP application', '75', 'Panel 15: Adverse event of special interest', '90', 'Panel 16: Transmission of electronic data', '117']\n\n###\n\n", "completion": "END"}